Addictive potential of novel treatments for refractory depression and anxiety

References

• Billioti de GageSMorideYDucruetTBenzodiazepine use and risk of Alzheimer’s disease: case-control studyBMJ20149349
   Google Scholar
• Billioti de GageSParienteABégaudBIs there really a link between benzodiazepine use and the risk of dementia?Expert Opin Drug Saf201514573374725691075
   PubMed Web of Science ®Google Scholar
• WuCSWangSCChangISLinKMThe association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims dataAm J Geriatr Psychiatry200917761462019546656
   PubMed Web of Science ®Google Scholar
• SchatzbergAFA word to the wise about ketamineAm J Psychiatry2014171326226424585328
   PubMed Web of Science ®Google Scholar
• WilliamsNRSchatzbergAFNMDA antagonist treatment of depressionCurr Opin Neurobiol20153611211726687375
   PubMed Web of Science ®Google Scholar
• NewportDJCarpenterLLMcDonaldWMKetamine and other NMDA antagonists: early clinical trials and possible mechanisms in depressionAm J Psychiatry20151721095096626423481
   PubMed Web of Science ®Google Scholar
• FondGLoundouARabuCKetamine administration in depressive disorders: a systematic review and meta-analysisPsychopharmacology (Berl)2014231183663367625038867
   PubMed Web of Science ®Google Scholar
• McGirrABerlimMBondDFleckMYathamLLamRA systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodesPsychol Med201545469370425010396
   PubMed Web of Science ®Google Scholar
• KellnerCHGreenbergRMAhleGMLiebmanLSElectroconvulsive therapy is a standard treatment; ketamine is not (yet)Am J Psychiatry20141717796
   Web of Science ®Google Scholar
• MurroughJWIosifescuDVChangLCAntidepressant efficacy of ketamine in treatment resistant major depression: a two-site randomized controlled trialAm J Psychiatry2013170101134114223982301
   PubMed Web of Science ®Google Scholar
• aan het RotMCollinsKAMurroughJWSafety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depressionBiol Psychiatry201067213914519897179
   PubMed Web of Science ®Google Scholar
• WilkinsonSTSanacoraGConsiderations on the off-label use of ketamine as a treatment for mood disordersJAMA2017318979379428806440
   PubMed Web of Science ®Google Scholar
• HuYDXiangYTFangJXSingle i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week studyPsychol Med201646362363526478208
   PubMed Web of Science ®Google Scholar
• DalyEJSinghJBFedgchinMEfficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trialJAMA Psychiatry201875213914829282469
   PubMed Web of Science ®Google Scholar
• FreedmanRFurther investigation of ketamineAm J Psychiatry2016173876176227477135
   PubMed Web of Science ®Google Scholar
• LiaoYTangJMaMFrontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging studyBrain20101332115212220519326
   PubMed Web of Science ®Google Scholar
• NiestersMMartiniCDahanAKetamine for chronic pain: risks and benefitsBr J Clin Pharmacol201477235736723432384
   PubMed Web of Science ®Google Scholar
• LiJHVicknasingamBCheungYWTo use or not to use: an update on licit and illicit ketamine useSubst Abuse Rehabil20112112024474851
   PubMedGoogle Scholar
• KennedySHLamRWMcIntyreRSCanadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological TreatmentsCan J Psychiatry201661954056027486148
   PubMed Web of Science ®Google Scholar
• MahliGSByrowYCassidyFKetamine: stimulating antidepressant treatment?BJPsych Open201623e5e927703782
   PubMedGoogle Scholar
• KolarDEmerging treatments in the management of patients with mood and anxiety disorders – practical and ethical considerationsOral presentation, XXXIVth International Congress on Law and Mental HealthJuly 12–17, 2015Vienna, Austria
   Google Scholar
• ParkerGBrotchieHMcClureGFletcherKPsychostimulants for managing unipolar and bipolar treatment-resistant melancholic depression: a medium-term evaluation of cost benefitsJ Affect Disord201315136036423810360
   PubMed Web of Science ®Google Scholar
• CorpSAGitlinMJAltshulerLLA review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorderJ Clin Psychiatry20147591010101825295426
   PubMed Web of Science ®Google Scholar
• MadhooMKeefeRRothRMLisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorderNeuropsychopharmacology20143961388139824309905
   PubMed Web of Science ®Google Scholar
• KolarDAlertness in patients with treatment resistant depressionKingston, OntarioQueen’s University Research Initiation Grant2013
   Google Scholar
• MooneyMEHerinDVSpeckerSBabbDLevinFRBrabowskiJPilot study of the effects of lisdexamfetamine on cocaine use: a randomized, double-blind, placebo-controlled trialDrug Alcohol Depend20151539410326116930
   PubMed Web of Science ®Google Scholar
• MilesWSSheridanJRussellBExtended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trialAddiction201310871279128623297867
   PubMed Web of Science ®Google Scholar
• WeyandtLLOsterDRMarracciniMEPharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulantsPsychol Res Behav Manag2014722324925228824
   PubMedGoogle Scholar
• RabinerDLStimulant prescription cautions: addressing misuse, diversion and malingeringCurr Psychiatry Rep201315737523712725
   PubMed Web of Science ®Google Scholar
• BensonKFloryKHumphreysKLLeeSSMisuse of stimulant medication among college students: a comprehensive review and meta-analysisClin Child Fam Psychol Rev201518507625575768
   PubMed Web of Science ®Google Scholar
• Chéron-BlumelAVictorri-VigneauCHardouinJMethylphenidate prescription: important recommendations to mitigate dependenceNeuropsychiatrie de l’Enfance et de l’Adolescence2012605S254
   Google Scholar
• PacherPBátkaiSKunosGThe endocannabinoid system as an emerging target of pharmacotherapyPharmacol Rev200658338946216968947
   PubMed Web of Science ®Google Scholar
• BotstwickJMBlurred boundaries: the therapeutics and politics of medical marijuanaMayo Clinic Proc201287172186
   Web of Science ®Google Scholar
• ShumanJHillJSaxonAJLevinFRControversies in marijuana legalization: taking the high roadMD Conference Express201515111214
   Google Scholar
• WhitingPFWolffRFDeshpandeSCannabinoids for medical use: a systematic review and meta-analysisJAMA2015313242456247326103030
   PubMed Web of Science ®Google Scholar
• TurnaJPattersonBVan AmeriganMIs cannabis treatment for anxiety, mood, and related disorders ready for prime time?Depress Anxiety201734111006101728636769
   PubMed Web of Science ®Google Scholar
• KolarDKolarMVCritical review of available treatment options for refractory depression and anxiety – clinical and ethical dilemmasMed Pregl2016695–617117629693845
   PubMedGoogle Scholar
• CrippaJAZuardiAWMartín-SantosRCannabis and anxiety: a critical review of the evidenceHum Psychopharm Clin200924515523
   PubMed Web of Science ®Google Scholar
• PapiniSSullivanGMHienDAShvilENeriaYToward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: a critical review of preclinical researchBiol Psychol201510481825448242
   PubMed Web of Science ®Google Scholar
• FraserGAThe use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD)CNS Neurosci Ther2009151848819228182
   PubMed Web of Science ®Google Scholar
• JeltyRHeberAFraserGBoisvertDThe efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design studyPsychoneuroendocrinology20155158558825467221
   PubMed Web of Science ®Google Scholar
• WareMAArnaud-TempeEStThe abuse potential of the synthetic cannabinoid nabiloneAddiction2010105349450320402993
   PubMed Web of Science ®Google Scholar
• KolarDControversies in psychiatrySynergy2017241379
   Google Scholar